ClinicalTrials.gg

Program

AB-1005

A development code.

Its studies are mostly in Parkinson Disease, led by Bayer.

Furthest: phase 2, since Sep 26, 20252 company-led studies, 2 open or runningNext primary completion: Apr 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer22 open or runningphase 2since Sep 26, 2025Sep 26, 2025Apr 30, 2028phase 2 · NCT07215403

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 26, 2025First study: phase 2 study in Parkinson DiseaseFirst studyNCT07215403 · 18 planned · United States
  2. Apr 28, 2026Phase 2 study in Parkinson DiseaseNCT07566429 · 8 planned · Japan

Ahead

  1. Apr 30, 2028Primary completion: phase 2 study in Parkinson DiseaseNCT07215403
  2. Jun 15, 2029Primary completion: phase 2 study in Parkinson DiseaseNCT07566429

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07566429Parkinson Disease · Japan2Not yet recruitingJun 15, 20298
NCT07215403Parkinson Disease · United States2Not yet recruitingApr 30, 202818

How it is read

Names in the registry

  • “AB-1005”, 2 entries

Codes read as this program: AB1005.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.